ArticleMicrobiome2025
Lysine restriction attenuates obesity-related anxiety-like behaviors via increasing Oscillibacter ruminantium-mediated tryptophol regulation.
Article in Microbiome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Treatment with saponins fromNutrition research and practice · 2026Article
- Comprehensive Analysis of miRNAs, mRNAs, and lncRNAs in Intestines of Breast- and Formula-Fed Pigs.Journal of animal physiology and animal nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe contribution of dietary interventions, particularly lysine-restricted diets (LRD), to ameliorating obesity-associated anxiety-like behaviors remains elusive, with limited evidence clarifying microbiota-metabolite-brain axis pathways involved.
resultsHerein, our results demonstrated that LRD attenuated high-fat diet (HFD)-induced anxiety-like behaviors while concomitantly reducing body weight and improving glucose metabolism. Furthermore, LRD significantly remodeled gut microbiota composition, most notably enriching the abundance of Oscillibacter. We then screened and identified that both viable and encapsulated Oscillibacter ruminantium alleviated obesity- and chronic restraint stress-induced anxiety-like behaviors, with microencapsulated formulations conferring superior anxiolytic efficacy. Notably, the obtained data revealed that LRD reversed HFD-induced the depletion of tryptophol, which was established as the metabolite of Oscillibacter ruminantium, and LRD could also alleviate the intestinal barrier impairment caused by HFD. Mechanistic results further demonstrated that tryptophol supplementation ameliorated HFD-driven anxiety-like phenotypes by inhibiting FTO-mediated reader protein IGF2BP1, and thereby reducing m⁶A modification of Lgr6 mRNA.
conclusionLRD attenuates obesity-associated anxiety-like behaviors by enriching Oscillibacter ruminantium and modulating tryptophol production, thereby activating the FTO-IGF2BP1-LGR6 signaling axis. These findings would indicate LRD as a microbiota-directed therapeutic strategy for neurobehavioral comorbidities of metabolic stress.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.